72-Hour CP-101,606 Infusion for Acute Ischemic Stroke Safety and Efficacy

This study focuses on a new research medication, CP-101,606, and its potential to safely and effectively treat acute ischemic stroke. An acute ischemic stroke occurs when blood flow to a part of the brain is blocked, usually by a blood clot. The study aims to help individuals who have experienced a stroke within the last 6 hours. By exploring this new treatment option, the study hopes to address the urgent need for effective stroke treatments that can minimize brain damage and improve recovery. During the study, participants receive either the research medication, CP-101,606, or a placebo through a 72-hour infusion. Neither the participants nor the researchers know who receives the medication or the placebo, ensuring unbiased results. The study's primary goals are to evaluate if the medication leads to marked neurological improvements and results in no or minimal neurological deficits by the end of the treatment period. These outcomes will help determine the potential benefits and risks associated with CP-101,606 for acute ischemic stroke treatment.